Jennifer provides health regulatory counsel to a range of industry clients, including pharmaceutical, biologic, and medical device manufacturers, digital health providers, clinical laboratories, pharmacies, health systems, hospitals, provider practice groups, skilled nursing facilities, home care agencies, health insurers, charitable foundations and companies that support or invest in the health industry.
Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.
Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.
TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation
August 16, 2023
Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.
Immunology Company argenx Announces $1.27 Billion Global Offering
July 26, 2023
Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.